LumaCyte, Inc. (“LumaCyte”) has completed a Series B financing, led by Malvern Panalytical Ltd (“Malvern Panalytical”), a subsidiary of Spectris plc (LON: SXS) (“Spectris“).
LumaCyte, headquartered in Charlottesville, Virginia, is an advanced research and bioanalytics instrumentation company that produces label-free, single cell analysis instrumentation where the use of antibody or genetic labeling is not required for cellular analysis. This technology utilizes Laser Force Cytology™ (LFC™) to measure optical and fluidic forces within a microfluidic channel to identify and measure the intrinsic cellular properties of each cell. The multivariate nature of the data has enabled a host of big data strategies and cloud computing capabilities that drive advanced analytics, allowing a deeper understanding of cell-based biological systems.
The proceeds of the fundraising will be used to scale LumaCyte’s commercial operations in the U.S. and Europe and further expansion of its product portfolio. In connection with the financing, LumaCyte will add Mark Fleiner, President, Malvern Panalytical, to its Board of Directors.
Malvern Panalytical, a UK-based scientific instrument manufacturer, specializes in empowering researchers by providing tools to comprehensively analyze a wide range of materials. Their instruments cover areas such as particle size, shape, chemical identity, zeta potential, protein charge, molecular weight, and more. This focus empowers scientists and engineers across diverse industries and organizations to tackle complex research challenges effectively, enabling them to optimize productivity and make critical advancements in their fields.
EuroConsult Capital LLC (“EC M&A”) acted as the exclusive financial advisor to Lumacyte.
